secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-05-26T11:15:41+00:00
Accession:  0001104659-26-065992
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Outlook Therapeutics appeal; BLA resubmission planned for June 2026
------------------------------------------------------------------------------

- FDA concluded substantial evidence of effectiveness for LYTENAVA (bevacizumab-vikg) for nAMD after FDR appeal.
- Company will resubmit BLA as Class 1 in June 2026; PDUFA decision expected within 60 days.
- Appeal resolves December 30, 2025 Complete Response Letter; FDA directs final labeling discussions.
- NORSE TWO trial results plus confirmatory data from NORSE EIGHT and other evidence supported effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/0001104659-26-065992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-065992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer